2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol | 129967-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol
• 英文别名: 3-(2'-hydroxy-4',6'-dimethylphenyl)-3,3-dimethylpropanol
• CAS: 129967-42-6
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: ZVXWXORBQGXYPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol 在 4-二甲氨基吡啶 、 potassium permanganate 、 水 、 溶剂黄146 、 三乙胺 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 57.0h， 生成 3-[2-(N-Boc-L-alanyloxy)-4,6-dimethylphenyl]-3,3-dimethylpropionic acid
  参考文献：
  名称：

  Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides That Utilizes a “Trimethyl Lock”-Facilitated Lactonization Reaction

  摘要：

  This paper describes a unique strategy for preparing cyclic prodrugs of peptides that have increased metabolic stability and increased cell membrane permeability when compared to the linear peptides. By taking advantage of a unique ''trimethyl lock''-facilitated lactonization system, an esterase-sensitive cyclic prodrug of a model hexapeptide H-Trp-Ala-Gly-Gly-Asp-Ala-OH was synthesized by linking the N-terminal amino group to the C-terminal carboxyl group. The key intermediate for both approaches was compound 9 with Boc-Ala attached to the phenol hydroxyl group of the ''trimethyl lock'' linker through an ester bond, which can then be incorporated into the peptide using a normal coupling reagent for peptide synthesis. The synthesis of the linear peptides was accomplished using both solution-phase and solid-phase approaches with the solution-phase approach having the advantage of using the key intermediate 9 most efficiently. Cyclization using standard high-dilution techniques provided cyclic prodrug 13. In 90% human plasma, prodrug 13 released the original peptide, as designed, through an apparent esterase-catalyzed hydrolysis of the phenol ester bond.

  DOI：

  10.1021/jo961778z
• 作为产物：
  描述：

  3,5-二甲基苯酚 在 lithium aluminium tetrahydride 、 甲烷磺酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 5.5h， 生成 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenol
  参考文献：
  名称：

  基于环化的自焚间隔基的合成和动力学研究†

  摘要：

  进行了基于环化过程的自焚间隔基拆卸的动力学分析。合成了五个属于两个不同系列的化合物，并确定了它们的动力学常数。给电子的取代基略有加速，但主要作用是空间位阻，而索普-英戈尔德作用确实特别有效。与基于消除过程的自焚性间隔基的比较表明，环化反应的速率相当或更低，但相应的间隔基更难调节。

  DOI：

  10.1039/c7ob00121e

文献信息

• [EN] NRTI THERAPIES<br/>[FR] THÉRAPIES NRTI
  申请人：UNIV LIVERPOOL

  公开号：WO2020128525A1

  公开（公告）日：2020-06-25

  Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants.

  聚合物前药（POP）材料实现了新的核苷类逆转录酶抑制剂（NRTI）治疗策略。这些材料是核苷类逆转录酶抑制剂的前药，以聚合物的形式存在。适用材料包括聚合物NRTI传递系统的产品，其中包括能够在给药后降解以释放NRTIs或NRTI前药的聚合物材料，这些NRTIs本身能够代谢成母体NRTIs。NRTIs可以选择自替诺福韦（TFV）、恩曲替滨（FTC）、拉米夫定（3TC）和MK-8591（EFdA）。该发明促进了长效（LA）疗程。这些材料的构造可以是注射剂或植入物的形式。
• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019136112A1

  公开（公告）日：2019-07-11

  The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.

  本发明提供了一种化合物，其化学式为(II)：一种吲哌酮胺2,3-二氧化酶（IDO）抑制剂，可用作治疗增生性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。其前药也已被披露。
• Molecular Umbrella as a Nanocarrier for Antifungals
  作者：Andrzej S. Skwarecki、Dorota Martynow、Maria J. Milewska、Sławomir Milewski

  DOI：10.3390/molecules26185475

  日期：——

  A molecular umbrella composed of two O-sulfated cholic acid residues was applied for the construction of conjugates with cispentacin, containing a “trimethyl lock” (TML) or o-dithiobenzylcarbamoyl moiety as a cleavable linker. Three out of five conjugates demonstrated antifungal in vitro activity against C. albicans and C. glabrata but not against C. krusei, with MIC90 values in the 0.22–0.99 mM range

  由两个O-硫酸化胆酸残基组成的分子伞被用于构建与顺喷辛的共轭物，其中包含一个“三甲基锁”（TML）或邻二硫代苄基氨基甲酰基部分作为可切割的接头。五分之三的偶联物显示出对白色念珠菌和光滑念珠菌的体外抗真菌活性，但对克柔念珠菌不具有抗真菌活性， MIC 90值在 0.22-0.99 mM 范围内并且不溶血。含有 TML-庚二酸接头的活性最强的偶联物24c 的抗真菌活性与完整的顺喷菌素相当。24c的结构类似物含有 Nap-NH 2荧光探针的 ，在念珠菌细胞中积累，含有 TML 的缀合物在白色念珠菌细胞的无细胞提取物中裂解。这些结果表明，分子伞可以成功地用作纳米载体，用于构建可切割的抗真菌缀合物。
• [EN] COMPOUNDS USEFUL IN HIV THERAPY<br/>[FR] COMPOSÉS UTILES DANS LA THÉRAPIE DU VIH
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020178767A1

  公开（公告）日：2020-09-10

  The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

  这项发明涉及公式（I）的化合物，其盐，药物组合物，以及治疗或预防HIV的方法。
• Design, Synthesis, and Cellular Uptake of Oligonucleotides Bearing Glutathione-Labile Protecting Groups
  作者：Hisao Saneyoshi、Takayuki Ohta、Yuki Hiyoshi、Takeo Saneyoshi、Akira Ono

  DOI：10.1021/acs.orglett.8b03501

  日期：2019.2.15

  Glutathione-labile protecting groups for phosphodiester moieties in oligonucleotides were designed, synthesized, and incorporated into oligonucleotides. The protecting groups on the phosphodiester moieties were cleaved in a buffer containing 10 mM glutathione, which was used as a model of intracellular fluid. Cellular uptake of oligonucleotides bearing glutathione-labile protecting groups was strongly affected

  设计，合成并合成寡核苷酸中对寡核苷酸中的磷酸二酯部分的谷胱甘肽不稳定的保护基。在含有10mM谷胱甘肽的缓冲液中裂解磷酸二酯部分上的保护基，该缓冲液用作细胞内液的模型。带有谷胱甘肽不稳定的保护基的寡核苷酸的细胞摄取受到保护基团的位置和数量的强烈影响。